Worldwide switch to bivalent oral polio vaccine to kick off on Sunday

A model of a poliovirus attaching to a receptor on a cell
Poliovirus (purple) attaching to a receptor

The trivalent oral polio vaccine has been instrumental in the near-eradication of the disease worldwide, but the vaccine still has some challenges that can be addressed by switching to a newer version. Starting this Sunday, the 155 countries that use the oral polio vaccine will move to the bivalent vaccine, the first time a changeover of this scale has been attempted.

The Global Polio Eradication Initiative, a public-private partnership spearheaded by the WHO, is leading the charge. The project is set to conclude on May 1, leaving a two-week window for the world to simultaneously make the switch.

The trivalent vaccine protects against poliovirus types 1, 2 and 3, but type 2 was declared eradicated in 1999. The advantages of cutting type 2 out of the vaccine are twofold: it reduces vaccine-associated polio and creates a stronger vaccine as it does not contain an extraneous component.

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

Sanofi ($SNY), Serum Institute of India, Bharat Biotech and GlaxoSmithKline ($GSK) are among the companies that manufacture WHO-prequalified trivalent polio vaccines. None of them will lose out in the switch, however, since every company that makes the trivalent vaccine also produces WHO-prequalified bivalent polio vaccines.

All oral polio vaccines are made with weakened live poliovirus, so there is a one-in-a-million risk of a weakened strain mutating and sickening people. However, according to the Global Polio Eradication Initiative, poliovirus type 2 is responsible for about 90% of paralysis cases caused by vaccine-associated polio. The switch will tamp down on the circulation of new strains of type 2 polio. Meanwhile, the Gates Foundation and the WHO are funding the development of a synthetic polio vaccine, which could eliminate the risk of vaccine-associated polio for good.

Despite the benefits of switching to the bivalent vaccine, there is a risk of declining population immunity to type 2 polio. The Global Polio Eradication Initiative has been scrambling to boost type 2 polio immunity levels ahead of the switch. It is also calling for a global stockpile of a monovalent vaccine against type 2 in case there is an outbreak of that polio type following the switch.

- read the Global Polio Eradication Initiative release
- and here's more about preparations for the switch

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.